Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Bugianesi

Showing results (121-130 of 326) with videos related to

Pageof 33
Sort By:
Hepatology (Baltimore, Md.)|August 30, 2008
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetesAnna Ludovica Fracanzani, Luca Valenti, Elisabetta Bugianesi, et al.
Gastroenterology|July 10, 2002
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinomaElisabetta Bugianesi, Nicola Leone, Ester Vanni, et al.
Gut|June 16, 2022
Current therapies and new developments in NASHJean-François Dufour, Quentin M Anstee, Elisabetta Bugianesi, et al.
Gastroenterology|November 26, 2009
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver diseaseLuca Valenti, Anna Ludovica Fracanzani, Elisabetta Bugianesi, et al.
Hepatology (Baltimore, Md.)|May 29, 2009
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver diseaseKerry-Lee Milner, David van der Poorten, Aimin Xu, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 27, 2011
Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitisFederico Salamone, Fabio Galvano, Antonella Marino Gammazza, et al.
Alimentary Pharmacology & Therapeutics|March 11, 2024
Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept studyAngelo Armandi, Helena Bespaljko, Alexander Mang, et al.
Diabetes Care|October 9, 2025
Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With TirzepatideCyrielle Caussy, Kenneth Cusi, Julio Rosenstock, et al.
Journal of Clinical Medicine|October 12, 2019
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's DiseaseDavide Giuseppe Ribaldone, Gian Paolo Caviglia, Amina Abdulle, et al.
The American Journal of Gastroenterology|May 31, 2017
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver DiseaseElisabetta Bugianesi, Carla Bizzarri, Chiara Rosso, et al.
Pageof 33

Showing results (121-130 of 326) with videos related to

Sort By:
Pageof 33
Hepatology (Baltimore, Md.)|August 30, 2008
Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetesAnna Ludovica Fracanzani, Luca Valenti, Elisabetta Bugianesi, et al.
Gastroenterology|July 10, 2002
Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinomaElisabetta Bugianesi, Nicola Leone, Ester Vanni, et al.
Gut|June 16, 2022
Current therapies and new developments in NASHJean-François Dufour, Quentin M Anstee, Elisabetta Bugianesi, et al.
Gastroenterology|November 26, 2009
HFE genotype, parenchymal iron accumulation, and liver fibrosis in patients with nonalcoholic fatty liver diseaseLuca Valenti, Anna Ludovica Fracanzani, Elisabetta Bugianesi, et al.
Hepatology (Baltimore, Md.)|May 29, 2009
Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver diseaseKerry-Lee Milner, David van der Poorten, Aimin Xu, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|December 27, 2011
Silibinin improves hepatic and myocardial injury in mice with nonalcoholic steatohepatitisFederico Salamone, Fabio Galvano, Antonella Marino Gammazza, et al.
Alimentary Pharmacology & Therapeutics|March 11, 2024
Short-term reduction of dietary gluten improves metabolic-dysfunction associated steatotic liver disease: A randomised, controlled proof-of-concept studyAngelo Armandi, Helena Bespaljko, Alexander Mang, et al.
Diabetes Care|October 9, 2025
Relationship Between Metabolic and Histological Responses in People With Metabolic Dysfunction- Associated Steatohepatitis With and Without Type 2 Diabetes: Participant-Level Exploratory Analysis of the SYNERGY-NASH Trial With TirzepatideCyrielle Caussy, Kenneth Cusi, Julio Rosenstock, et al.
Journal of Clinical Medicine|October 12, 2019
Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn's DiseaseDavide Giuseppe Ribaldone, Gian Paolo Caviglia, Amina Abdulle, et al.
The American Journal of Gastroenterology|May 31, 2017
Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver DiseaseElisabetta Bugianesi, Carla Bizzarri, Chiara Rosso, et al.
Pageof 33